5th Annual Recombinant Antibodies Conference

17-19 January 2012

London, UK

Louise Holliday will be speaking at Visiongain’s 5th Annual Recombinant Antibodies conference.  The conference will allow delegates to:

• Network with key decision makers at leading companies
• Improve the potency of IgG molecules for ADCC, ADCP and CDC applications
• Enhance immune effector functions through targeted Fc region engineering
• Increase in vivo circulation time with conjugated immunoglobulins
• Extend pharmacokinetic half-life and exposure
• Better utilise, deploy and evaluate in silico tools during early-phase research
• Optimise antigen-binding domains
• Engineer decreased immunogenicity, cross-reactivity and in vivo toxicity
• Assess new technologies for selecting antibody attributes
• Maximise site-specific drug loading for bispecific antibodies
• Obtain new data on inflammatory disease, and solid and liquid cancer targets
• Block activation of angiogenic signalling pathways and disrupt the tumour microenvironment

Conference website

http://www.visiongain.com/Conference/314/5th-Annual-Recombinant-Antibodies

Further information

Delegate fees
Conference and workshop: £1699 + vat
Conference only: £1299 + vat
Workshop only: £599 + vat

for further information about the event contact Visiongain by email: conferences@visiongainglobal.com

Meeting location

Visiongain Conference Centre, 230 City Road, London, EC1V 2QY, UK.